Literature DB >> 19888036

Effect of injectable and oral contraceptives on serum lipids.

Abbey B Berenson1, Mahbubur Rahman, Gregg Wilkinson.   

Abstract

OBJECTIVE: To estimate the effects of using depot medroxyprogesterone acetate (DMPA) or oral contraceptives (OCs) containing 20 micrograms ethinyl estradiol and 0.15 mg desogestrel on serum lipid levels.
METHODS: Serum lipids were measured at baseline and every 6 months thereafter for 3 years in 703 white, African-American, and Hispanic women using DMPA, OC, or nonhormonal birth control. Those who discontinued DMPA were followed for up to 2 additional years. Participants completed questionnaires containing demographic and behavioral measures every 6 months and underwent 24-hour dietary recalls annually. Mixed-model regression analyses and general-estimating-equations procedures were used to estimate changes over time in lipids by method along with their predictors.
RESULTS: Users of OCs experienced significantly greater increases in levels of triglycerides, total cholesterol, very-low-density lipoprotein (VLDL) cholesterol, and high-density lipoprotein (HDL) cholesterol than did nonhormonal-contraceptive users (P<.001). However, no difference was noted in the low-density lipoprotein (LDL) cholesterol:HDL ratio between OC users and nonhormonal-contraceptive users. Among DMPA users, HDL levels initially decreased for 6 months but then returned to baseline. The LDL:HDL ratio rose in the first 6 months of DMPA use but then dropped back to baseline over the next 24 months. After DMPA was discontinued, triglyceride, VLDL, and HDL levels were significantly higher in women who used OCs than in those who chose nonhormonal (P<.05) methods.
CONCLUSION: Use of very-low-dose OCs containing desogestrel can elevate lipid levels. Users of DMPA were at increased risk of developing an abnormally low HDL level as well as an abnormally high LDL level and an increase in the LDL:HDL cholesterol ratio, although these effects appeared to be temporary. LEVEL OF EVIDENCE: II.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19888036      PMCID: PMC2853747          DOI: 10.1097/AOG.0b013e3181b76bea

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  34 in total

1.  Effects of two combined oral contraceptives containing ethinyl estradiol 20 microg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism.

Authors:  Christine Klipping; Joachim Marr
Journal:  Contraception       Date:  2005-06       Impact factor: 3.375

2.  Effects of the injectable contraceptive depot medroxyprogesterone acetate in Thai women with liver fluke infestation: final results.

Authors:  R A Grossman; W Asawasena; S Chalpati; D Taewtong; S Tovanabutra
Journal:  Bull World Health Organ       Date:  1979       Impact factor: 9.408

3.  Clinical experience of a combined oral contraceptive with very low dose ethinyl estradiol.

Authors:  M Akerlund
Journal:  Acta Obstet Gynecol Scand Suppl       Date:  1997

4.  Metabolic and endocrine effects of the desogestrel-containing oral contraceptive Mircette.

Authors:  S L Berga
Journal:  Am J Obstet Gynecol       Date:  1998-07       Impact factor: 8.661

5.  Both a combined oral contraceptive and depot medroxyprogesterone acetate impair endothelial function in young women.

Authors:  Patrícia Margareth Lizarelli; Wellington Paula Martins; Carolina Sales Vieira; Gustavo Mafaldo Soares; Sílvio Antônio Franceschini; Rui Alberto Ferriani; Maristela Carbol Patta
Journal:  Contraception       Date:  2008-10-01       Impact factor: 3.375

6.  Insulin sensitivity and lipid metabolism with oral contraceptives containing chlormadinone acetate or desogestrel: a randomized trial.

Authors:  Angelo Cagnacci; Serena Ferrari; Alessandra Tirelli; Renata Zanin; Annibale Volpe
Journal:  Contraception       Date:  2008-10-16       Impact factor: 3.375

7.  Long-term effects of Depo-Provera on carbohydrate and lipid metabolism.

Authors:  D F Liew; C S Ng; Y M Yong; S S Ratnam
Journal:  Contraception       Date:  1985-01       Impact factor: 3.375

8.  Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.

Authors:  P Virutamasen; C Wongsrichanalai; P Tangkeo; Y Nitichai; D Rienprayoon
Journal:  Int J Gynaecol Obstet       Date:  1986-08       Impact factor: 3.561

9.  Fasting plasma lipids, lipoproteins and apolipoproteins in Nigerian women using combined oral and progestin-only injectable contraceptives.

Authors:  O O Oyelola
Journal:  Contraception       Date:  1993-05       Impact factor: 3.375

10.  Serum lipids and lipoproteins during therapeutic amenorrhea induced by lynestrenol and depot-medroxyprogesterone acetate.

Authors:  K Huovinen; M J Tikkanen; S Autio; T Härkönen; L Lommi; S Varonen; M L Wilska
Journal:  Acta Obstet Gynecol Scand       Date:  1991       Impact factor: 3.636

View more
  16 in total

Review 1.  Cardiovascular risk assessment and cholesterol management in adolescents: getting to the heart of the matter.

Authors:  Holly C Gooding; Sarah D de Ferranti
Journal:  Curr Opin Pediatr       Date:  2010-08       Impact factor: 2.856

2.  Cardiovascular disease incidence among females in South Carolina by type of oral contraceptives, 2000-2013: a retrospective cohort study.

Authors:  Marsha E Samson; Swann A Adams; Anwar T Merchant; Whitney D Maxwell; Jiajia Zhang; Charles L Bennett; James R Hebert
Journal:  Arch Gynecol Obstet       Date:  2016-07-11       Impact factor: 2.344

3.  In Reply.

Authors:  Thomas Römer
Journal:  Dtsch Arztebl Int       Date:  2020-04-03       Impact factor: 5.594

Review 4.  The Extending Spectrum of NPC1-Related Human Disorders: From Niemann-Pick C1 Disease to Obesity.

Authors:  Amel Lamri; Marie Pigeyre; William S Garver; David Meyre
Journal:  Endocr Rev       Date:  2018-04-01       Impact factor: 19.871

5.  Effect of hormonal contraceptives on vitamin B12 level and the association of the latter with bone mineral density.

Authors:  Abbey B Berenson; Mahbubur Rahman
Journal:  Contraception       Date:  2012-03-28       Impact factor: 3.375

Review 6.  Oestrogen and anti-androgen therapy for transgender women.

Authors:  Vin Tangpricha; Martin den Heijer
Journal:  Lancet Diabetes Endocrinol       Date:  2016-12-02       Impact factor: 32.069

7.  Oral Contraceptive Use and Risks of Cancer in the NIH-AARP Diet and Health Study.

Authors:  Kara A Michels; Louise A Brinton; Ruth M Pfeiffer; Britton Trabert
Journal:  Am J Epidemiol       Date:  2018-08-01       Impact factor: 4.897

8.  Oral contraceptives modify DNA methylation and monocyte-derived macrophage function.

Authors:  Ilaria Campesi; Manuela Sanna; Angelo Zinellu; Ciriaco Carru; Laura Rubattu; Pamela Bulzomi; Giuseppe Seghieri; Giancarlo Tonolo; Mario Palermo; Giuseppe Rosano; Maria Marino; Flavia Franconi
Journal:  Biol Sex Differ       Date:  2012-01-27       Impact factor: 5.027

9.  Amelioration of lipid abnormalities by vitamin therapy in women using oral contraceptives.

Authors:  Shahnaz Torkzahrani; Afrooz Heidari; Zohreh Mostafavi-Pour; Majid Ahmadi; Fatemeh Zal
Journal:  Clin Exp Reprod Med       Date:  2014-03-14

10.  Effect of hormonal contraceptives on lipid profile and the risk indices for cardiovascular disease in a Ghanaian community.

Authors:  George A Asare; Sheila Santa; Robert A Ngala; Bernice Asiedu; Daniel Afriyie; Albert Gb Amoah
Journal:  Int J Womens Health       Date:  2014-06-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.